

James D Berry

List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/10056239/publications.pdf](https://exaly.com/author-pdf/10056239/publications.pdf)

Version: 2025-02-01

71

PR articles

3,885

PR citations

96772

33

PR h-index

110435

58

g-index

83

documents

5441

doc citations

93013

36

h-index

7222

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Identifying amyotrophic lateral sclerosis through interactions with an internet search engine. <i>Muscle and Nerve</i> , 2024, 69, 40-47.	2.2	5
2	A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS—FTD. <i>Nature Medicine</i> , 2024, 30, 382-393.	39.5	105
3	The relationship of rate and pause features to the communicative participation of people living with <sc>ALS</sc>. <i>Muscle and Nerve</i> , 2024, 70, 217-225.	2.2	2
4	Access for ALL in ALS: A large—scale, inclusive, collaborative consortium to unlock the molecular and genetic mechanisms of amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2024, 70, 1140-1150.	2.2	7
5	Safety and activity of <sc>anti—CD14</sc> antibody <sc>IC14</sc> (atibuclimab) in <sc>ALS</sc>: Experience with expanded access protocol. <i>Muscle and Nerve</i> , 2023, 67, 354-362.	2.2	18
6	Expanded access protocol (<sc>EAP</sc>) program for access to investigational products for amyotrophic lateral sclerosis (<sc>ALS</sc>). <i>Muscle and Nerve</i> , 2023, 67, 456-463.	2.2	6
7	Wearable device and smartphone data quantify ALS progression and may provide novel outcome measures. <i>Npj Digital Medicine</i> , 2023, 6, .	10.7	46
8	Novel genetic variants in <i>MAPT</i> and alterations in tau phosphorylation in amyotrophic lateral sclerosis post—mortem motor cortex and cerebrospinal fluid. <i>Brain Pathology</i> , 2022, 32, .	4.3	26
9	A randomized <sc>placebo—controlled</sc> phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2022, 65, 291-302.	2.2	91
10	Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development. <i>Annals of Neurology</i> , 2022, 91, 165-175.	6.3	77
11	Phase <sc>2B</sc> randomized controlled trial of <sc>NP001</sc> in amyotrophic lateral sclerosis: Pre—specified and post hoc analyses. <i>Muscle and Nerve</i> , 2022, 66, 39-49.	2.2	28
12	Using Smartphones to Reduce Research Burden in a Neurodegenerative Population and Assessing Participant Adherence: A Randomized Clinical Trial and Two Observational Studies. <i>JMIR MHealth and UHealth</i> , 2022, 10, e31877.	4.9	24
13	Protocol for psychometric evaluation of the Amyotrophic Lateral Sclerosis - Bulbar Dysfunction Index (ALS-BDI): a prospective longitudinal study. <i>BMJ Open</i> , 2022, 12, e060102.	2.0	5
14	Validity of Off-the-Shelf Automatic Speech Recognition for Assessing Speech Intelligibility and Speech Severity in Speakers With Amyotrophic Lateral Sclerosis. <i>Journal of Speech, Language, and Hearing Research</i> , 2022, 65, 2128-2143.	1.7	26
15	An expanded access protocol of <sc>RT001</sc> in amyotrophic lateral sclerosis—Initial experience with a lipid peroxidation inhibitor. <i>Muscle and Nerve</i> , 2022, 66, 421-425.	2.2	18
16	Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents. <i>Drugs</i> , 2022, 82, 1367-1388.	11.8	80
17	Identifying patterns in amyotrophic lateral sclerosis progression from sparse longitudinal data. <i>Nature Computational Science</i> , 2022, 2, 605-616.	11.8	45
18	The human gut microbiota in people with amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 186-194.	2.6	93

#	ARTICLE	IF	PR CITATIONS
19	Long-term survival of participants in the <sc>CENTAUR</sc> trial of sodium phenylbutyrate-taurursodiol in <sc>amyotrophic lateral sclerosis</sc>. Muscle and Nerve, 2021, 63, 31-39.	2.2	168
20	Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 186.	15.1	122
21	lbudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial. NeuroImage: Clinical, 2021, 30, 102672.	3.4	34
22	Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry's Research Notification Mechanism. Journal of Medical Internet Research, 2021, 23, e28021.	4.9	10
23	In Traditional Medicare, Modest Growth In The Home Care Workforce Largely Driven By Nurse Practitioners. Health Affairs, 2021, 40, 478-486.	5.5	11
24	Patient reported outcomes in ALS: characteristics of the self-entry ALS Functional Rating Scale-revised and the Activities-specific Balance Confidence Scale. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 467-477.	2.6	26
25	Two Distinct Clinical Phenotypes of Bulbar Motor Impairment in Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2021, 12, .	2.4	16
26	Development and validation of a machine-learning ALS survival model lacking vital capacity (VC-Free) for use in clinical trials during the COVID-19 pandemic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 22-32.	2.6	11
27	Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact. Neuroscience and Biobehavioral Reviews, 2021, 127, 958-978.	7.1	47
28	Co-Occurrence of Hypernasality and Voice Impairment in Amyotrophic Lateral Sclerosis: Acoustic Quantification. Journal of Speech, Language, and Hearing Research, 2021, 64, 4772-4783.	1.7	17
29	“You Say Severe, I Say Mild” Toward an Empirical Classification of Dysarthria Severity. Journal of Speech, Language, and Hearing Research, 2021, 64, 4718-4735.	1.7	48
30	Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2021, 59, 683-702.	3.8	45
31	Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle and Nerve, 2020, 62, 156-166.	2.2	87
32	Plasma neurofilament light predicts mortality in patients with stroke. Science Translational Medicine, 2020, 12, .	12.7	78
33	Trial of Sodium Phenylbutyrate-taurursodiol for Amyotrophic Lateral Sclerosis. New England Journal of Medicine, 2020, 383, 919-930.	43.7	475
34	Lipocalin-2 is increased in amyotrophic lateral sclerosis. Muscle and Nerve, 2020, 62, 272-283.	2.2	16
35	Understanding the needs of people with ALS: a national survey of patients and caregivers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 355-363.	2.6	49
36	Longitudinal biomarkers in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 1103-1116.	3.8	105

#	ARTICLE	IF	PR CITATIONS
37	Patient reported outcome measures (PROMs) in amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2020, 267, 1754-1759.	3.5	24
38	Reliability and validity of speech & pause measures during passage reading in ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 42-50.	2.6	53
39	Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral sclerosis. <i>Neurology</i> , 2019, 92, .	1.0	5
40	Learning from history: Lord Brain and Hashimoto's encephalopathy. <i>Practical Neurology</i> , 2019, 19, 316-320.	2.1	5
41	Class I and II histone deacetylase expression is not altered in human amyotrophic lateral sclerosis: Neuropathological and positron emission tomography molecular neuroimaging evidence. <i>Muscle and Nerve</i> , 2019, 60, 443-452.	2.2	11
42	Adjusted cost analysis of video televisits for the care of people with amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2019, 60, 147-154.	2.2	30
43	Design and results of a smartphone-based digital phenotyping study to quantify ALS progression. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 873-881.	3.8	93
44	Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS. <i>BMC Neurology</i> , 2019, 19, .	2.1	19
45	Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. <i>Neurology</i> , 2019, 92, .	1.0	126
46	Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2019, 9, .	3.5	33
47	Assessing Oromotor Capacity in ALS: The Effect of a Fixed-Target Task on Lip Biomechanics. <i>Frontiers in Neurology</i> , 2019, 10, .	2.4	19
48	NurOwn, phase 2, randomized, clinical trial in patients with ALS. <i>Neurology</i> , 2019, 93, .	1.0	144
49	Correlating serum micrnas and clinical parameters in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2018, 58, 261-269.	2.2	96
50	Experience with telemedicine in a multi-disciplinary ALS clinic. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 143-148.	2.6	46
51	An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 242-249.	2.6	41
52	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. <i>Neuron</i> , 2018, 97, 1267-1288.	11.1	660
53	Minimally Detectable Change and Minimal Clinically Important Difference of a Decline in Sentence Intelligibility and Speaking Rate for Individuals With Amyotrophic Lateral Sclerosis. <i>Journal of Speech, Language, and Hearing Research</i> , 2018, 61, 2757-2771.	1.7	71
54	Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: A quantitative speech analysis. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2849-2856.	2.7	38

#	ARTICLE	IF	PR CITATIONS
55	Expanded autologous regulatory T-lymphocyte infusions in ALS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, .	6.9	157
56	Phosphorylated neurofilament heavy chain: A biomarker of survival for <sc><i>C9ORF72</i></sc>-associated amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2017, 82, 139-146.	6.3	110
57	Developing multidisciplinary clinics for neuromuscular care and research. <i>Muscle and Nerve</i> , 2017, 56, 848-858.	2.2	59
58	The diagnostic utility of patient-report and speech-language pathologists'™ ratings for detecting the early onset of bulbar symptoms due to ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 358-366.	2.6	72
59	Poly(GP) proteins are a useful pharmacodynamic marker for <i>C9ORF72</i>-associated amyotrophic lateral sclerosis. <i>Science Translational Medicine</i> , 2017, 9, .	12.7	211
60	Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. <i>Muscle and Nerve</i> , 2017, 56, 1077-1084.	2.2	48
61	Predicting Speech Intelligibility Decline in Amyotrophic Lateral Sclerosis Based on the Deterioration of Individual Speech Subsystems. <i>PLoS ONE</i> , 2016, 11, e0154971.	2.4	113
62	Preclinical rodent toxicity studies for long term use of ceftriaxone. <i>Toxicology Reports</i> , 2015, 2, 1396-1403.	3.7	13
63	Electrical impedance myography in the evaluation of the tongue musculature in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2015, 52, 584-591.	2.2	35
64	Amyotrophic Lateral Sclerosis: Review. <i>Seminars in Neurology</i> , 2015, 35, 469-476.	1.8	66
65	Neuroprotective agents target molecular mechanisms of disease in ALS. <i>Drug Discovery Today</i> , 2015, 20, 65-75.	6.8	33
66	FUS is sequestered in nuclear aggregates in ALS patient fibroblasts. <i>Molecular Biology of the Cell</i> , 2014, 25, 2571-2578.	2.5	50
67	Predicting success: Optimizing phase II ALS trials for the transition to phase III. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2014, 15, 1-8.	2.6	12
68	Outcome measures in amyotrophic lateral sclerosis clinical trials. <i>Clinical Investigation</i> , 2014, 4, 605-618.	0.3	60
69	The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 162-168.	2.6	106
70	Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis. <i>PLoS ONE</i> , 2013, 8, e61177.	2.4	98
71	New considerations in the design of clinical trials for amyotrophic lateral sclerosis. <i>Clinical Investigation</i> , 2011, 1, 1375-1389.	0.3	34